LT3137093T - Alzheimerio ligos (ad) gydymas ir prevencija - Google Patents

Alzheimerio ligos (ad) gydymas ir prevencija

Info

Publication number
LT3137093T
LT3137093T LTEP15720059.3T LT15720059T LT3137093T LT 3137093 T LT3137093 T LT 3137093T LT 15720059 T LT15720059 T LT 15720059T LT 3137093 T LT3137093 T LT 3137093T
Authority
LT
Lithuania
Prior art keywords
alzheimer
disease
prevention
treatment
Prior art date
Application number
LTEP15720059.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Markus Mandler
Achim Schneeberger
Arne Von Bonin
Frank Mattner
Walter Schmidt
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of LT3137093T publication Critical patent/LT3137093T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP15720059.3T 2014-04-29 2015-04-29 Alzheimerio ligos (ad) gydymas ir prevencija LT3137093T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14166355 2014-04-29
EP14166354 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
LT3137093T true LT3137093T (lt) 2017-12-11

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15720059.3T LT3137093T (lt) 2014-04-29 2015-04-29 Alzheimerio ligos (ad) gydymas ir prevencija

Country Status (18)

Country Link
US (1) US10478454B2 (enExample)
EP (2) EP3269376B1 (enExample)
JP (1) JP6692755B2 (enExample)
KR (1) KR102388363B1 (enExample)
CN (1) CN106659738B (enExample)
AU (1) AU2015254663B2 (enExample)
CA (1) CA2946928C (enExample)
CY (1) CY1119674T1 (enExample)
DK (1) DK3137093T3 (enExample)
ES (2) ES2824763T3 (enExample)
HR (1) HRP20171896T1 (enExample)
HU (1) HUE037501T2 (enExample)
LT (1) LT3137093T (enExample)
NO (1) NO3137093T3 (enExample)
PL (1) PL3137093T3 (enExample)
PT (1) PT3137093T (enExample)
SI (1) SI3137093T1 (enExample)
WO (1) WO2015165966A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535924A (zh) 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) * 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
EP1007040B1 (en) * 1997-08-21 2002-05-08 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CN104436212A (zh) * 2010-03-29 2015-03-25 诺华股份有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) * 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Also Published As

Publication number Publication date
EP3269376A1 (en) 2018-01-17
ES2824763T3 (es) 2021-05-13
AU2015254663A1 (en) 2016-11-10
CN106659738B (zh) 2021-02-09
HRP20171896T1 (hr) 2018-02-23
PL3137093T3 (pl) 2018-06-29
CA2946928A1 (en) 2015-11-05
KR20160145822A (ko) 2016-12-20
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
DK3137093T3 (en) 2017-12-11
AU2015254663B2 (en) 2020-04-02
CN106659738A (zh) 2017-05-10
SI3137093T1 (en) 2018-01-31
PT3137093T (pt) 2017-12-19
EP3137093B1 (en) 2017-09-13
HUE037501T2 (hu) 2018-08-28
EP3137093A1 (en) 2017-03-08
CY1119674T1 (el) 2018-04-04
JP2017518275A (ja) 2017-07-06
JP6692755B2 (ja) 2020-05-13
CA2946928C (en) 2023-01-31
WO2015165966A1 (en) 2015-11-05
EP3269376B1 (en) 2020-07-15
NO3137093T3 (enExample) 2018-02-10
US20170049812A1 (en) 2017-02-23
US10478454B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL247085B (en) Methods for treating Alzheimer's disease
EP3142707A4 (en) Methods and compositions for prevention or treatment of a disease
HUE047952T2 (hu) Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
ZA201605341B (en) Methods of treating alzheimer's disease
EP3104776A4 (en) Diagnosis and treatment of respiratory disorders
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
ZA201800037B (en) Diagnosis and treatment of infectious disease
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
PT3151814T (pt) Tratamento de uma lesão da pele
GB201413530D0 (en) Treatment and prevention of malaria
GB201408387D0 (en) Treatment of respiratory disorders
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
IL251135A0 (en) A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201622116D0 (en) Treatment of liver disease
EP3188744A4 (en) Methods for treatment and prevention of vascular disease
GB201621398D0 (en) Treatment of emt-associated disease